Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy

Clinical Medicine Insights: Cardiology

Volumn 11, Issue , 2017, Pages

  Sultan, Marla B ^a   Gundapaneni, Balarama ^b   Schumacher, Jennifer ^a   Schwartz, Jeffrey H ^a  

^a PFIZER INC   (United States)

^b SYNEOS HEALTH   (United States)

Author keywords

cardiac amyloidosis; heart failure; tafamidis; Transthyretin

Indexed keywords

EID: 85043300497     PISSN: None     EISSN: 11795468     Source Type: Journal    
DOI: 10.1177/1179546817730322     Document Type: Article

References (15)

1. Ruberg FL, Berk JL., Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126:1286–1300.
2. Ruberg FL, Maurer MS, Judge DP. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164:222–228.e1.
3. Connors LH, Doros G, Sam F, Badiee A, Seldin DC, Skinner M., Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy. Amyloid. 2011;18:157–159.
4. Pinney JH, Whelan CJ, Petrie A. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2:e000098.
5. Rowczenio DM, Noor I, Gillmore JD. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35:E2403–E2412.
6. Gorevic PD, Prelli FC, Wright J, Pras M, Frangione B., Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. J Clin Invest. 1989;83:836–843.
7. Jacobson DR, Gorevic PD, Buxbaum JN., A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology. Am J Hum Genet. 1990;47:127–136.
8. Jacobson DR, Pastore RD, Yaghoubian R. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336:466–473.
9. Gertz MA, Falk RH, Skinner M, Cohen AS, Kyle RA., Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol. 1985;55:1645.
10. Bulawa CE, Connelly S, Devit M. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109:9629–9634.
11. Maurer MS, Grogan DR, Judge DP. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015;8:519–526.
12. Falk R, Maurer M, Fedson S. Tafamidis stabilizes transthyretin and improves clinical outcomes in transthyretin amyloid cardiomyopathy. J Card Fail. 2011;17:S56.
13. Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016;23:178–183.
14. Rapezzi C, Merlini G, Quarta CC. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120:1203–1212.
15. Grogan M, Scott CG, Kyle RA. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68:1014–1020.